Lixte Biotechnology News

Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing

AccesswireSep 11 13:00 ET

Express News | LIXTE Biotechnology Receives USPTO Notice Of Allowance For Patent On Combining LB-100 With Cancer Immunotherapies, Strengthening Its Intellectual Property Portfolio And Advancing Cancer Treatment Trials

BenzingaSep 4 08:36 ET

Why Nordstrom Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

BenzingaAug 28 05:23 ET

Express News | Lixte Biotechnology Begins First Patient Dosing In New Clinical Trial With Netherlands Cancer Institute And Roche For Metastatic Colorectal Cancer

BenzingaAug 26 08:31 ET

First Patient Dosed With LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating With NKI, Supported by Major Pharma Company

GlobeNewswireAug 26 08:30 ET

Express News | First Patient Dosed With Lixte’s Lb-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating With Nki, Supported by Major Pharma Company

ReutersAug 26 08:30 ET

LIXTE Biotechnology Provides Update On Recent Activities And Developments; Collaboration With NKI And Funding Support For New Colorectal Cancer Clinical Trial By Major Pharma Co; Preclinical Data Published In Journal EMBO Reports Shows LB-100 As...

BenzingaAug 19 08:42 ET

Lixte Biotechnology Says Jan Schellens Joins Company as Chief Medical Officer >LIXT

Dow JonesAug 19 08:32 ET

Express News | Lixte Biotechnology Provides Update on Recent Activities and Developments

ReutersAug 19 08:30 ET

LIXTE Biotechnology Holdings to Present at Two Investor Conferences

GlobeNewswireAug 15 08:30 ET

Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event

AccesswireAug 14 22:50 ET

10-Q: Q2 2024 Earnings Report

SECAug 8 16:10 ET · Announcements

Express News | Lixte Biotechnology Holdings Inc - Will Provide Its Lead Compound, Lb-100, and Roche Will Provide Atezolizumab for Trial

ReutersJun 14 11:01 ET

Express News | Lixte Biotechnology Holdings Announces Collaboration on a New Colon Cancer Clinical Trial

ReutersJun 14 11:00 ET

Express News | LIXTE Biotechnology Announces Collaboration With Roche And Netherlands Cancer Institute For Clinical Trial On LB-100's Effectiveness In Enhancing Immune Recognition Of Colon Cancer Cells In MSI Low Metastatic Colon Cancer

BenzingaJun 14 09:31 ET

Express News | Lixte Biotechnology Holdings to Collaborate With Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial

ReutersJun 14 09:30 ET

Express News | Lixte Biotechnology: Agreement to Conduct a Phase 1B/2 Clinical Trial of Lb-100, Combined With Atezolizumab for Patients With Metastatic Colon Cancer

ReutersJun 14 08:37 ET

Express News | Lixte Biotechnology: Got Into Clinical Trial Agreement With Netherlands Cancer Institute

ReutersJun 14 08:37 ET

Express News | LIXTE Biotechnology Shares Are Trading Higher After the Company Announced the Publication of Pre-clinical Data in the Journal EMBO Reports Showing That LB-100 Increases Recognition of Colon Cancer Cells by the Immune System

BenzingaJun 6 08:37 ET

Scientific Journal Reports Findings That Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

GlobeNewswireJun 6 08:30 ET